Gonorrhea Clinical Trial Pipeline Demonstrates Strong Momentum With 12+ Leading Pharma Companies Advancing Innovation | DelveInsight

DelveInsight's "Gonorrhea Pipeline Insight 2026" report delivers extensive analysis of more than 12 companies and 12+ investigational therapies shaping the Gonorrhea treatment landscape. The study outlines detailed drug profiles across clinical and preclinical stages and evaluates therapies based on product category, development phase, route of administration, and molecular class. It also identifies discontinued and inactive assets within the pipeline.

Download DelveInsight's comprehensive Gonorrhea Pipeline Report to explore emerging therapies, key Gonorrhea Companies, and future Gonorrhea treatment landscapes @ Gonorrhea Pipeline Outlook Report- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Gonorrhea Pipeline Report
• On December 11, 2025, GSK plc (LSE/NYSE: GSK) announced that the US FDA approved a supplemental New Drug Application (sNDA) for Blujepa (gepotidacin). The approval broadens its indication as an oral therapy for adults and pediatric patients aged 12 years and older (weighing at least 45 kg) with uncomplicated urogenital gonorrhea caused by susceptible Neisseria gonorrhoeae strains who have limited or no alternative treatment options. This expansion follows the FDA's earlier approval of gepotidacin for uncomplicated urinary tract infections (uUTIs) in eligible female patients.
• DelveInsight's findings highlight a dynamic and competitive environment, with 12+ companies actively developing more than 12 pipeline therapies targeting Gonorrhea.
• Major players in the Gonorrhea therapeutic space include Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Summit Therapeutics, and others.
• Promising therapeutic candidates under development include Gepotidacin, Ceftriaxone, Azithromycin, GSK2140944, Solithromycin, Tinidazole, EVO100, and additional novel agents.

Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ Gonorrhea Clinical Trials and Studies- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The report provides a detailed overview of the disease, current pipeline dynamics, and a comprehensive therapeutic evaluation of key investigational drugs. It also addresses existing unmet needs in Gonorrhea management.

Gonorrhea Overview
Gonorrhea is a widespread sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae, which primarily infects the mucosal linings of the reproductive tract, throat, and eyes. Transmission occurs through vaginal and anal contact, and many infected individuals remain asymptomatic, facilitating silent spread. When symptoms are present, they may include painful urination, abnormal discharge, and pelvic or testicular discomfort.
If left untreated, Gonorrhea can result in severe complications such as pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and increased vulnerability to HIV infection. Although antibiotics remain the cornerstone of treatment, rising antimicrobial resistance has created significant therapeutic challenges.

Gonorrhea Emerging Drug Profiles
• Gepotidacin: GlaxoSmithKline
Gepotidacin (GSK2140944) is a first-in-class triazaacenaphthylene topoisomerase inhibitor. It acts by targeting bacterial DNA gyrase and topoisomerase IV-critical enzymes involved in bacterial replication. Its novel mechanism enables activity against pathogens resistant to conventional antibiotics, including fluoroquinolones. The therapy is currently in Phase III development for uncomplicated urinary tract infections and Gonorrhea.

• Zoliflodacin: Entasis Therapeutics
Zoliflodacin (ETX0914) is an orally administered antibacterial agent and a novel spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor. It is being evaluated in Phase III clinical trials for the treatment of Gonorrhea.

Explore DelveInsight's expert-driven report today! @ Gonorrhea Unmet Needs- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Insights Offered in the Gonorrhea Pipeline Report
• Comprehensive analysis of companies developing Gonorrhea therapies, including their aggregate pipeline portfolios.
• Segmentation of therapeutic candidates across early-, mid-, and late-stage development.
• Evaluation of both active and discontinued development programs.
• Classification of pipeline drugs by development stage, administration route, molecular target, mono- or combination therapy, mechanism of action, and molecule type.
• Detailed assessment of strategic collaborations, licensing agreements, funding activities, and partnerships shaping the future Gonorrhea market.
Gonorrhea Companies
Key organizations advancing Gonorrhea research include Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Summit Therapeutics, and other emerging innovators.

Therapeutic Categorization
The pipeline report evaluates Gonorrhea therapies by route of administration, including:
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Additionally, therapies are classified by molecule type, such as:
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies

Download DelveInsight's latest report to gain strategic insights into upcoming Gonorrhea Therapies and key Gonorrhea Developments @ Gonorrhea Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Gonorrhea Pipeline Report
• Coverage: Global
• Key Companies: Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Summit Therapeutics, and others
• Key Therapies: Gepotidacin, Ceftriaxone, Azithromycin, GSK2140944, Solithromycin, Tinidazole, EVO100, among others
• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, or Both
• Clinical Stage Segmentation: Discovery, Preclinical, Phase I, Phase II, Phase III

Find out in DelveInsight's exclusive Gonorrhea Pipeline Report-access it now! @ Gonorrhea Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. Gonorrhea Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. DelveInsight's Analytical Perspective
7. Commercial Evaluation
8. Collaboration Deals
9. Late-Stage Products (Phase III)
10. Gepotidacin Profile
11. Mid-Stage Products (Phase II)
12. F 598: Alopexx Pharmaceuticals
13. Early-Stage Products (Phase I)
14. Preclinical and Discovery Programs
15. GneX 12: TherapyX
16. Inactive Products
17. Key Companies
18. Key Products
19. Unmet Needs
20. Market Drivers and Barriers
21. Future Perspectives and Conclusion
22. Analyst Views
23. Key Companies
24. Appendix

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.